Loading stock data…
OFIX
$12.21+0.03 (+0.25%)
Pre-Market$12.22+0.01 (+0.08%)· Last close May 13
Orthofix Medical Inc., together with its subsidiaries, operates as a medical technology company in the United States, Italy, the United Kingdom, France, Germany, Brazil, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Orthofix Medical Inc. in the Healthcare sector is trading at $12.21. Wall Street consensus targets $17.25 (4 analysts), implying a +41.3% move over the next 12 months. The stock is currently 28% below its 52-week high of $16.99, remaining 12.0% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +41.3% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Sector + growth-aware fair-multiple estimate. Fair P/E = sector-anchor + (ROE × 25) + (max(revenue growth, earnings growth) × 30), capped at 1.6× sector. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. The sector anchor (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) keeps quality compounders from being mechanically penalized against utility multiples. Result is a normalised multiple gauge — not a price target.
Current Price$12.21
Potential Downside
0%
Whystock Fair Value$12.21
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus4 analysts
Buy
Mean target$17.25+41.3%
Range$14.00 – $20.00
Fundamentals
Orthofix Medical Inc., together with its subsidiaries, operates as a medical technology company in the United States, Italy, the United Kingdom, France, Germany, Brazil, and internationally. It operates through two segments, Global Spine and Global L...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$482.33M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.82
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-27.49%
Volume
Today's trading volume
240,870
Recent News
Orthofix Medical Inc. (NASDAQ:OFIX) Just Reported, And Analysts Assigned A US$17.25 Price Target
Investors in Orthofix Medical Inc. ( NASDAQ:OFIX ) had a good week, as its shares rose 2.6% to close at US$12.07...
Orthofix Medical Q1 Earnings Call Highlights
Orthofix Medical (NASDAQ:OFIX) reported first-quarter 2026 results that management said reflect steadier execution, improving stability, and the early benefits of actions taken to reset its Spine commercial channel. Total global net sales for the quarter ended March 31, 2026 were $196.4 million, up
Orthofix Medical Inc. Q1 2026 Earnings Call Summary
Moby summary of Orthofix Medical Inc.'s Q1 2026 earnings call
Orthofix (OFIX) Q1 2026 Earnings Transcript
Massimo will start with business performance and operational highlights. Julie Andrews will follow with her financial results and guidance, then we'll open up the call for Q&A. With that, I'll turn the call over to Massimo, who will discuss how our early year execution and recent operational actions are beginning to support improved performance as we move through the year.
How The Orthofix Medical (OFIX) Story Is Shifting After Q4 Models And 2026 Guidance
Orthofix Medical is in the spotlight as Street price targets reset from earlier levels in the low to mid US$20s into a tighter US$17 to US$20 range, while a model fair value of US$17.25 remains unchanged. These revisions are tied to refreshed Q4 inputs, updated 2026 guidance, and a longer timeline to the company’s adjusted EBITDA margin goals, which are shaping both bullish and cautious views. Read on to see how to track this evolving narrative and what the latest assumptions may mean for...